Table 4.
Cox proportional hazards model analysis of the clinicopathological and treatment features in terms of locoregional recurrence-free survival
| Feature | Relative risk | 95% CI | p |
|---|---|---|---|
| Age, years | 0.009 | ||
| <35 | 1.00 | ||
| ≥35 | 0.57 | 0.38–0.87 | |
| Menopausal status | 0.103 | ||
| Premenopausal | 1.00 | ||
| Postmenopausal | 1.26 | 0.95–1.67 | |
| Tumor size | <0.001 | ||
| T1 | 1.00 | ||
| T2 | 1.72 | 1.27–2.33 | |
| T3 | 2.18 | 1.40–3.41 | |
| Multifocality/multicentricity | 0.031 | ||
| Yes | 1.00 | ||
| No | 0.62 | 0.40–0.96 | |
| Histological type | 0.599 | ||
| ILC | 1.00 | ||
| IDC | 0.80 | 0.52–1.23 | |
| IDLC | 0.80 | 0.39–1.63 | |
| Axillary lymph node status | 0.018 | ||
| Negative | 1.00 | ||
| Positive | 1.51 | 1.07–2.12 | |
| Surgery | 0.001 | ||
| Mastectomy | 1.00 | ||
| Breast-conserving | 1.92 | 1.29–2.85 | |
| Chemotherapy | 0.863 | ||
| Yes | 1.00 | ||
| No | 1.03 | 0.70–1.52 | |
| Hormonal therapy | <0.001 | ||
| Yes | 1.00 | ||
| No | 1.82 | 1.39–2.38 | |
| Radiotherapy | 0.001 | ||
| Yes | 1.00 | ||
| No | 1.87 | 1.31–2.66 |
CI: confidence interval; ILC: invasive lobular carcinoma; IDC: invasive ductal carcinoma; IDLC: mixed invasive ductal and lobular carcinoma